Aditxt, Inc. (ADTX)
US Market

Aditxt, Inc. (ADTX) Stock Price & Analysis


ADTX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.83 - $28.49
Previous Close$0.88
Average Volume (3M)160.22K
Market Cap
Enterprise Value-$1.95M
Total Cash (Recent Filing)$9.24M
Total Debt (Recent Filing)$3.56M
Price to Earnings (P/E)>-0.1
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-66.86
Shares Outstanding4,295,633
10 Day Avg. Volume39,590
30 Day Avg. Volume160,221
Standard Deviation0.26
Financial Highlights & Ratios
Price to Book (P/B)0.29
Price to Sales (P/S)4.91
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-2.28
Enterprise Value/Gross Profit-71.92
Enterprise Value/Ebitda0.05
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Aditxt, Inc.’s price range in the past 12 months?
Aditxt, Inc. lowest stock price was $0.83 and its highest was $28.49 in the past 12 months.
    What is Aditxt, Inc.’s market cap?
    Currently, no data Available
    When is Aditxt, Inc.’s upcoming earnings report date?
    The company’s upcoming earnings report date is not yet available.
    How were Aditxt, Inc.’s earnings last quarter?
    Currently, no data Available
    Is Aditxt, Inc. overvalued?
    According to Wall Street analysts Aditxt, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
      Does Aditxt, Inc. pay dividends?
      Aditxt, Inc. does not currently pay dividends.
      What is Aditxt, Inc.’s EPS estimate?
      Aditxt, Inc.’s EPS estimate for its next earnings report is not yet available.
      How many shares outstanding does Aditxt, Inc. have?
      Aditxt, Inc. has 4,295,633 shares outstanding.
        What happened to Aditxt, Inc.’s price movement after its last earnings report?
        Currently, no data Available
        Which hedge fund is a major shareholder of Aditxt, Inc.?
        Currently, no hedge funds are holding shares in ADTX


        Aditxt, Inc. Stock Smart Score

        Not Ranked
        This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
        Learn more about TipRanks Smart Score

        Company Description

        Aditxt, Inc.

        ADiTx Therapeutics Inc is a pre-clinical stage, life sciences company which focuses on prolong life and enhance life quality of transplanted patients. The firm develop products designed to induce tolerance to transplanted organs. The firm's immunosuppressive (anti-rejection) drugs has made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues.


        Top 5 ETFs holding ADTX

        Currently, no data available
        Please return soon. This page is being updated.
        Up to five ETFs with an Outperform Smart Score that hold ADTX. The ETFs are listed according to market value of ADTX within the ETF


        Forecast EPS vs Actual EPS

        Currently, no data available
        Please return soon. This page is being updated.

        Similar Stocks
        Price & Change
        Statera BioPharma
        Vyant Bio
        Ensysce Biosciences

        Popular Stocks

        What's Included in PREMIUM?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis